The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.
SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...
By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...
Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback